SEONGNAM, South Korea, Aug. 5, 2024 /PRNewswire/ -- SK pharmteco, a global contract development, manufacturing, and analytical testing organization serving both the small molecule and cell & gene therapy industry, and Rznomics Inc., a South Korea-based biopharmaceutical company specializing in the development of RNA-based gene therapeutics, have signed a memorandum of understanding (MOU) for a contract development and manufacturing partnership.
Leading analytical lab service providers are increasingly diversifying testing strategies leveraging advanced technologies to enhance efficiency and speed in an era marked by unprecedented therapeutic breakthroughs.
King of Prussia, PA (May 21, 2024)—SK pharmteco, a global contract development, manufacturing, and analytical testing organization serving the pharmaceutical and cell & gene therapy industry, today announced the upcoming launch of Lentiviral Vector (LVV) Analytical Services, a comprehensive suite of analytical testing solutions specifically designed for LVV and cell therapy programs. Coinciding with the launch is the commissioning of a new, state-of-the-art 20,000-square-foot CGMP testing facility, located on SK pharmteco’s King of Prussia campus, with dedicated laboratory space specifically designed for replication-competent lentivirus (RCL) testing and molecular based analytics. The full platform is available for R&D testing now, with full CGMP testing capabilities in July 2024.